Recludix

2 known investors

Recludix Pharma develops oral precision small-molecule therapies for people with inflammatory diseases, using a platform that inhibits previously undruggable SH2 domains to target dysregulated cellular signaling pathways. Its pipeline includes an oral STAT6 inhibitor (REX-8756) for conditions such as atopic dermatitis and asthma.